all report title image

PRURITUS THERAPEUTICS MARKET ANALYSIS

Pruritus Therapeutics Market, by Drug Class (Corticosteroids, Antihistamines, Counterirritants, Immunosuppressant, Calcineurin Inhibitors, and Others), by Indication (Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Psoriasis, and Others), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Dec 2024
  • Code : CMI4492
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Pruritus is also known as itching, which is an annoying and uncontrollable sensation that causes one to scratch, in order to relieve the discomfort. Dry skin, skin diseases, and pregnancy are some of the possible causes of itchiness.

Rashes, bumps or any visible signs of irritation may appear on the skin during pruritus. Some diseases or conditions that cause pruritus include contact dermatitis, scabies, food or substance allergies, allergic eczema, psoriasis, urticaria, systemic lupus erythematous (SLE), and chicken pox. Some allergic reactions may lead to anaphylaxis, a severe form of allergic reaction which can also be life threatening.

Few natural treatments used for pruritus include application of coconut oil, vitamin E, and honey topically. Medications such as antihistamine and corticosteroids might help in the treatment of pruritus especially in case of contact dermatitis.

Global Pruritus Therapeutics Market – Dynamics

The increase in the number of cases of dermatitis and allergic diseases is expected to propel the growth of global pruritus therapeutics market. For instance, according to the article published in the Indian Journal of Dermatology in 2020, dermatitis was the most common subgroup of hypersensitivity diseases, accounting for 24.5% of all cases of allergic skin disorders. Contact dermatitis (17.54% of the total) was found to be the most commonly detected skin disease in the dermatitis group of diseases.

Moreover, according to European Academy of Allergy and Clinical Immunology, 2016, over 150 million Europeans suffer from chronic allergic diseases, and it is estimated that half of the European Union (EU) population will be affected with chronic allergy disorders by 2025.

The increasing product launches and approvals is expected to boost global pruritus therapeutics market growth. For instance, on May 26, 2020, Sanofi, a global biopharmaceutical company dedicated to human health, announced that the U.S. Food and Drug Administration (FDA) has approved its Dupixent (dupilumab) for children between 6 to 11 years with moderate-to-severe atopic dermatitis (eczema) with pruritus as one of its major symptom. This disease in children is not adequately controlled by topical prescription therapies or those therapies that are contraindicated. Dupixent is the only biologic medicine approved for this patient population in treating eczema with pruritus.

Furthermore, rising mergers, agreements, and acquisitions by market players are expected to propel the global pruritus therapeutics market over the forecast period. For instance, on August 24, 2020, MC2 Therapeutics, a pharmaceutical company that develops topical therapies, announced a collaboration agreement with EPI Health, LLC to commercialize WYNZORA Cream in the U.S. EPI Health is a leading pharmaceutical company in dermatology community. WYNZORA Cream was approved by the U.S. Food and Drug Administration (FDA) on July 20, 2020) for the topical treatment of plaque psoriasis, a common cause of psoriasis itching (pruritus) in adults. These factors are expected to support global pruritus therapeutics market growth over the forecast period.

Global Pruritus Therapeutics Market – Regional Insights

Among regions, North America is expected to account for the largest share in global pruritus therapeutics market over the forecast period, owing to the approval of treatments from regulatory authorities for treatment of pruritus. For instance, on March 8, 2021, the U.S. Food and Drugs Administration (FDA) accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.  The Prescription Drug User Fee Act (PDUFA) target action date for KORSUVA is August 23, 2021. KORSUVA is marketed by Vifor Pharma, a global pharmaceutical company, which develops products for precision patient care and Cara Therapeutics, Inc., a clinical stage biopharmaceutical company focused on producing new chemical entities to alleviate pruritus.

Moreover, due to rise in agreements and sales partnerships within market players, Europe may witness a lucrative growth in global pruritus therapeutics market over the forecast period. For instance, on February 17, 2021, Almirall S.A., a global biopharmaceutical company, and MC2 Therapeutics, a commercial stage pharmaceutical company, which develops topical therapies for autoimmune and chronic inflammatory conditions, confirmed that MC2 Therapeutics granted Almirall exclusive European rights to commercialize WYNZORA Cream for the treatment of plaque psoriasis, a common cause of psoriasis itching (pruritus) in adults. These factors are expected to support global pruritus therapeutics market growth over the forecast period.

Global Pruritus Therapeutics Market    – Taxonomy

By Drug Class:

  • Corticosteroids
  • Antihistamines
  • Counterirritants
  • Immunosuppressant
  • Calcineurin Inhibitors
  • Others

By Indication:

  • Atopic Dermatitis
  • Allergic Contact Dermatitis
  • Urticaria
  • Psoriasis
  • Others

By Route of Administration:

  • Oral
  • Parenteral
  • Topical

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Global Pruritus Therapeutics Market – Competitive landscape

Key players operating in the global pruritus therapeutics market include Pfizer Inc., Sanofi S.A., Amgen Inc., Almirall S.A , NJ Novartis Pharmaceuticals Corporation, MC2 Therapeutics A/S, EPI Health LLC, Allergan Plc., Astellas Pharma US, Inc., Mylan N.V., Johnson & Johnson, Vifor Pharma group, Cara Therapeutics Inc., and Aventis Pharma Ltd.

Share

About Author

Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.

Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.

Missing comfort of reading report in your local language? Find your preferred language :

Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Select a License Type





Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.